Table 3 Clinical performance according to revised FDI criteria

From: Clinical performance of low-shrinkage giomer compared to nanohybrid resin composite in proximal restorations after one year: a randomized clinical trial

FDI	Follow-up	Beautifil LS					Filtek Z250XT					P value
FDI		Success			Failure		Success			Failure
Score		1	2	3	4	5	1	2	3	4	5
A1	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (96.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.3173
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22 (91.7)	2 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0.1447
	P value	1.0000					0.368
A2	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (96.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.3173
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22 (91.7)	2 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0.1447
	P value	1.0000					0.368
A3	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23 (92.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.1530
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23 (95.8)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0.3074
	P value	1.0000					0.368
B1	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.8864
	P value	1.0000					0.368
B2	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.8864
	P value	1.0000					0.368
B3	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	23 (92.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (96.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.5555
	12 months	23 (92.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.1614
	P value	1.0000					0.368
F1	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (96.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.3173
	12 months	23 (92.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (96.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.0)	0.2208
	P value	1.0000					0.368
F2	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (96.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.3173
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23 (95.8)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0.3074
	P value	1.0000					0.368
F3	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (96.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.3173
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23 (95.8)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0.3074
	P value	1.0000					0.368
F4	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23 (95.8)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0.3074
	P value	1.0000					0.368
F5	Baseline	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1.0000
	6 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (96.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.3173
	12 months	25 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23 (95.8)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0.3074
	P value	1.0000					0.368

Back to article page

Table 3 Clinical performance according to revised FDI criteria

Search

Quick links